C4 Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, and its news flow reflects active clinical development, collaborations and capital markets activity. Company updates frequently highlight progress with cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and certain lymphomas, as well as broader pipeline and platform achievements.

News for C4 Therapeutics often centers on clinical data milestones, such as Phase 1 results for cemsidomide in combination with dexamethasone, acceptance of data for oral presentation at scientific meetings, and plans for registrational trials like the Phase 2 MOMENTUM study. Releases also cover developments in non-Hodgkins lymphoma cohorts and updates on other degrader programs, including CFT8919 for EGFR-mutant non-small cell lung cancer and CFT1946 for BRAF V600 mutant solid tumors.

Investors following CCCC news will also see collaboration announcements and research milestones. Examples include the clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide with elranatamab in multiple myeloma, milestone achievements in partnerships with Biogen, Roche and Merck KGaA, Darmstadt, Germany, and regulatory steps such as IND acceptance for BIIB142, an IRAK4 degrader designed by C4 Therapeutics.

Financial and corporate updates are another key news category. The company regularly reports quarterly financial results, cash runway guidance, equity offerings and changes to its capital structure via press releases and Form 8-K filings. For readers tracking CCCC, this news page aggregates these clinical, scientific, collaboration and financing updates in one place, making it easier to monitor how C4 Therapeutics is advancing its targeted protein degradation pipeline over time.